201 related articles for article (PubMed ID: 12068339)
61. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
62. Tolerance to bronchodilating effects of salmeterol in COPD.
Donohue JF; Menjoge S; Kesten S
Respir Med; 2003 Sep; 97(9):1014-20. PubMed ID: 14509555
[TBL] [Abstract][Full Text] [Related]
63. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study.
Stockley RA; Chopra N; Rice L
Thorax; 2006 Feb; 61(2):122-8. PubMed ID: 16443706
[TBL] [Abstract][Full Text] [Related]
64. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
[TBL] [Abstract][Full Text] [Related]
65. Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group.
Jones KP
Thorax; 1994 Oct; 49(10):971-5. PubMed ID: 7974313
[TBL] [Abstract][Full Text] [Related]
66. Lower inhaled steroid requirement with a fluticasone/salmeterol combination in family practice patients with asthma or COPD.
Schermer TR; Albers JM; Verblackt HW; Costongs RJ; Westers P
Fam Pract; 2007 Apr; 24(2):181-8. PubMed ID: 17251178
[TBL] [Abstract][Full Text] [Related]
67. Effect of tiotropium on night-time awakening and daily rescue medication use in patients with COPD.
Calverley PM; Rennard SI; Clerisme-Beaty E; Metzdorf N; Zubek VB; ZuWallack R
Respir Res; 2016 Mar; 17():27. PubMed ID: 26971242
[TBL] [Abstract][Full Text] [Related]
68. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
Celik G; Kayacan O; Beder S; Durmaz G
Respiration; 1999; 66(5):434-9. PubMed ID: 10516540
[TBL] [Abstract][Full Text] [Related]
69. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.
Vestbo J; Soriano JB; Anderson JA; Calverley P; Pauwels R; Jones P;
Respir Med; 2004 Nov; 98(11):1045-50. PubMed ID: 15526804
[TBL] [Abstract][Full Text] [Related]
70. Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.
Stockley RA; Whitehead PJ; Williams MK
Respir Res; 2006 Dec; 7(1):147. PubMed ID: 17196106
[TBL] [Abstract][Full Text] [Related]
71. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD.
Briggs DD; Covelli H; Lapidus R; Bhattycharya S; Kesten S; Cassino C
Pulm Pharmacol Ther; 2005; 18(6):397-404. PubMed ID: 16179215
[TBL] [Abstract][Full Text] [Related]
72. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
[TBL] [Abstract][Full Text] [Related]
73. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
[TBL] [Abstract][Full Text] [Related]
74. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.
Appleton S; Poole P; Smith B; Veale A; Lasserson TJ; Chan MM
Cochrane Database Syst Rev; 2006 Jul; (3):CD001104. PubMed ID: 16855959
[TBL] [Abstract][Full Text] [Related]
75. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease.
Cazzola M; Di Perna F; Centanni S; Califano C; Donner CF; D'Amato M; D'Amato G
Thorax; 1999 Dec; 54(12):1083-6. PubMed ID: 10567627
[TBL] [Abstract][Full Text] [Related]
76. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study.
Cazzola M; Matera MG; Santangelo G; Vinciguerra A; Rossi F; D'Amato G
Respir Med; 1995 May; 89(5):357-62. PubMed ID: 7638371
[TBL] [Abstract][Full Text] [Related]
77. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis.
Hordvik NL; Sammut PH; Judy CG; Colombo JL
Pediatr Pulmonol; 1999 Jan; 27(1):43-53. PubMed ID: 10023791
[TBL] [Abstract][Full Text] [Related]
78. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Voduc N; Fitzpatrick M; Webb KA
Eur Respir J; 2004 Jul; 24(1):86-94. PubMed ID: 15293609
[TBL] [Abstract][Full Text] [Related]
79. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation.
Jones PW; Wilson K; Sondhi S
Respir Med; 2003 Jan; 97(1):20-6. PubMed ID: 12556006
[TBL] [Abstract][Full Text] [Related]
80. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study.
Kottakis J; Cioppa GD; Creemers J; Greefhorst L; Lecler V; Pistelli R; Overend T; Till D; Rapatz Gn; Le Gros V; Bouros D; Siafakas N
Can Respir J; 2002; 9(2):107-15. PubMed ID: 11972164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
